دورية أكاديمية

Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.

التفاصيل البيبلوغرافية
العنوان: Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
المؤلفون: Jain, Rohit K., Yang, Yuanquan, Chadha, Juskaran, Zhang, Jingsong, Raymond, Sarah, Oschmann, Erika, Poehlman, Trey, Fan, Wenyi, Kim, Youngchul, Dhillon, Jasreman, Chahoud, Jad, Chatwal, Monica Sheila, Sonpavde, Guru P.
المصدر: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS713-TPS713, 193p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2024.42.4_suppl.TPS713